The Incidence and Survival of Acute de novo Leukemias in Estonia and in a Well-Defined Region of Western Sweden during 1997–2001: A Survey of Patients Aged 16–64 Years

Wennström, Lovisa; Safai‐Kutti, Soodabeh; Stockelberg, Dick; Holmberg, Erik; Palk, Katrin; Varik, Mirja; Viigimaa, Iige; Vaht, Krista; Luik, Ene; Everaus, Hele; Kutti, Jack

doi:10.1159/000329526

Cited by 3 publications

(2 citation statements)

References 38 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our survival rate of 35% at 5 years was lower than that reported from Sweden (44% at 4 years) and the Republic of Korea (58.2% at 3 years) but higher than in Estonia (23.1% at 3 years) [20,21,22]. In several reports, multivariate analysis of prognostic factors showed that age ≥60 years was a statistically significant poor prognostic factor for CR, OS, remission duration and relapse-free survival [23,24]; this was the case in our group, in which there was also a high rate of early death (39%) in patients ≥60 years, and those with a previous disease had the worst outcome, which agrees with previous studies [25,26].…”

Section: Discussioncontrasting

confidence: 56%

Characteristics and Clinical Evolution of Patients with Acute Myeloblastic Leukemia in Northeast Mexico: An Eight-Year Experience at a University Hospital

et al. 2014

View full text Add to dashboard Cite

Background/Objective: Acute myeloid leukemia (AML) is the most common acute leukemia in adults. We documented the characteristics and results of treatment of patients with AML at a single reference center. Methods: Patients diagnosed with AML between June 2003 and July 2011 at a university hospital in northeast Mexico were studied. Overall survival (OS) and event-free survival (EFS) were determined, and risk factors were analyzed with respect to their influence on prognosis. Results: A total of 132 AML patients were included. Median age was 32 years. Complete remission (CR) was achieved by 55% of patients. CR was achieved by 65.1% of patients <60 years (n = 109), compared to 8.7% of those >60 years (n = 23; p < 0.001). In all, 39% of patients >60 years suffered an early death, compared to 14.7% of those <60 years (p < 0.001). OS for patients with AML was 35%, whereas EFS was 32%. On multivariate analysis, patients >60 years had a lower OS and EFS (p < 0.001). A total of 28% of patients received a transplant, and they had higher OS and EFS. Conclusions: Our patients were considerably younger and had remarkably lower survival rates than reported for other populations; those >60 years had a higher early death rate, and fewer of these patients achieved CR.

show abstract

Section: Discussioncontrasting

confidence: 56%

Characteristics and Clinical Evolution of Patients with Acute Myeloblastic Leukemia in Northeast Mexico: An Eight-Year Experience at a University Hospital

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Thereafter, we conducted a prospective study in the years 1997-2001 [3]. In Estonia, there was a remarkable and welcome improvement in survival, particularly in acute myeloid leukemia (AML) patients [3,4]. …”

Section: Introductionmentioning

confidence: 99%

Acute de novo Leukemia in Estonia and Western Sweden 1982-2006: Positive Trend in the Survival of Acute Leukemia over 25 Years

Hulegårdh

Punab²,

Holmberg³

et al. 2016

Acta Haematol

Self Cite

View full text Add to dashboard Cite

This study focuses on the incidence, treatment, and survival of de novo acute leukemia in a 25-year perspective in western Sweden and Estonia. At the beginning of our study, Estonia was a part of the Eastern bloc with planned economy, but since 1991 it is a member of the European Union and transforming into a market economy. Survival rates have steadily increased in both countries. However, a gap between their survival curves remains. Based on our data, it is difficult to explain the big difference in the 5-year relative survival in favor of western Sweden (55 vs. 22%). In Germany, there was a big difference in overall cancer survival between East and West Germany after the fall of the iron curtain, but today no difference is seen. Differences in survival are probably due to a higher proportion of intense chemotherapy regimens and a higher rate of hematopoietic stem cell transplantations in Sweden. Other important factors might be better supportive care and diagnostics as well as better adjuvant therapy. Better staff training and conditions in wards are also factors that might play an essential role.

show abstract

Sequential population-based studies over 25 years on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982–2006: a survey of patients aged ≥65 years

et al. 2013

View full text Add to dashboard Cite

Estonia regained independence in 1991 after five decades of occupation by the Soviet Union. The present population-based survey was carried out over five consecutive 5-year study periods (1982-2006) on the incidence and survival of de novo acute leukemia patients aged ≥65 years at diagnosis in Estonia and in a well-defined area in western Sweden. During the study period of retrospective work (1982-1996), the first 10 years were carried out while Estonia was still under the mentorship of the Soviet Union. Over these years, Estonian hematologists did not have access to therapeutic measures readily available to Swedish hematologists, and the results for survival for western Swedish patients with acute myeloid leukemia (AML) far exceeded those of their Estonian counterparts. However, the results for acute lymphoblastic leukemia were equally dismal in the two countries. Subsequent prospective population-based studies were carried out during the years 1997-2006. A gradual improvement as to long-term relative survival of the Estonian AML patients was observed. When studying 2002-2006, no difference as regards relative survival at 5 years was anymore present between the two countries. Over the first 20 years of our population-based studies, it was repeatedly observed that the age-standardized incidence rate particularly for de novo AML was considerably higher for the western Swedish as compared to the Estonian cohorts. During the last 5-year study period (2002-2006), no such difference between the two countries was present, indicating that some true changes in the reporting procedure in Estonia had occurred.

show abstract

The Incidence and Survival of Acute de novo Leukemias in Estonia and in a Well-Defined Region of Western Sweden during 1997–2001: A Survey of Patients Aged 16–64 Years

Cited by 3 publications

References 38 publications

Characteristics and Clinical Evolution of Patients with Acute Myeloblastic Leukemia in Northeast Mexico: An Eight-Year Experience at a University Hospital

Characteristics and Clinical Evolution of Patients with Acute Myeloblastic Leukemia in Northeast Mexico: An Eight-Year Experience at a University Hospital

Acute de novo Leukemia in Estonia and Western Sweden 1982-2006: Positive Trend in the Survival of Acute Leukemia over 25 Years

Sequential population-based studies over 25 years on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982–2006: a survey of patients aged ≥65 years

Contact Info

Product

Resources

About